SCHEMBL148909

SCHEMBL148909

C[C@@H](OP(=O)(O)O)[C@@H](NC(=O)CCCCCCS)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.40
LPAR3 Q9UBY5 3/20 0.38
PLA2G4A P47712 2/20 0.36
FAAH O00519 2/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 2/20 0.36
PTPN1 P18031 1/20 0.35
HDAC3 O15379 3/20 0.35
HDAC4 P56524 3/20 0.35
HDAC1 Q13547 3/20 0.35
HDAC7 Q8WUI4 3/20 0.35
HDAC2 Q92769 3/20 0.35
HDAC10 Q969S8 3/20 0.35
HDAC11 Q96DB2 3/20 0.35
HDAC8 Q9BY41 3/20 0.35
HDAC6 Q9UBN7 3/20 0.35
HDAC9 Q9UKV0 3/20 0.35
HDAC5 Q9UQL6 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1512990 1.00 PIN1 (0.40) PIN1LPAR3PLA2G4AFAAHMEN1
SCHEMBL16093888 1.00 PIN1 (0.40) PIN1LPAR3PLA2G4AFAAHMEN1
SCHEMBL17821203 1.00 PIN1 (0.40) PIN1LPAR3PLA2G4AFAAHMEN1
SCHEMBL17821198 1.00 PIN1 (0.40) PIN1LPAR3PLA2G4AFAAHMEN1
SCHEMBL2441860 0.88 FAAH (0.51) LPAR3PLA2G4AFAAHMEN1MAPK1
SCHEMBL18681852 0.82 EPHX2 (0.39) FAAHMEN1MAPK1KMT2AEPHX2
Phosphoric Acid SCHEMBL17821202 0.82 FAAH (0.40) PLA2G4AFAAHMEN1MAPK1KMT2A
Phosphoric Acid SCHEMBL3390206 0.82 FAAH (0.40) PLA2G4AFAAHMEN1MAPK1KMT2A
Phosphoric Acid SCHEMBL17821199 0.82 FAAH (0.40) PLA2G4AFAAHMEN1MAPK1KMT2A
SCHEMBL22503908 0.79 PIN1 (0.36) PIN1LPAR3PLA2G4AFAAHMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739293-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS AZURA OPHTHALMICS LTD (IL) 2026-05-13 EP claimed
EP-4739291-A2 ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES AZURA OPHTHALMICS LTD (IL) 2026-05-13 EP claimed
WO-2026041906-A1 SEMI-SOLID PHARMACEUTICAL COMPOSITION MICRO-DISPENSER Azura Ophthalmics Ltd. (IL) 2026-02-26 WO claimed
US-12453495-B2 Hormone electrochemical biosensor TRUSTEES OF BOSTON UNIVERSITY (US) 2025-10-28 US claimed
WO-2025012700-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS Azura Ophthalmics Ltd. (IL) 2025-01-16 WO claimed
WO-2025012701-A2 ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES Azura Ophthalmics Ltd. (IL) 2025-01-16 WO claimed
WO-2024100454-A2 COMPOSITION AND METHODS FOR IMPROVING SIGNS AND SYMPTOMS OF OCULAR DISORDERS Azura Ophthalmics Ltd. (IL) 2024-05-16 WO claimed
US-20240099614-A1 HORMONE ELECTROCHEMICAL BIOSENSOR TRUSTEES OF BOSTON UNIVERSITY (US) 2024-03-28 US claimed
CN-117059160-A Method for screening plant active substances for inhibiting methane generation of ruminants and application thereof 南京农业大学 2023-11-14 CN claimed
CN-110585057-B Anti-inflammatory grease cleaning composition and preparation method and application thereof 吉开平 2022-07-12 CN claimed
EP-1782071-A2 COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR PROMEGA CORPORATION (US) 2007-05-09 EP claimed
EP-1373571-B1 FUNCTIONAL SURFACE DISPLAY OF POLYPEPTIDES UNIV DES SAARLANDES WISSENS UN (DE) 2006-11-22 EP claimed
WO-2006093529-A2 COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR PROMEGA CORPORATION (US) 2006-09-08 WO claimed
US-20050272114-A1 Substrates for covalent tethering to proteins JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2005-12-08 US claimed
CN-1695633-A Facial paralysis capsule and its preparation method KANG DECHENG (CN) 2005-11-16 CN claimed
EP-1583818-A2 B12 DEPENDENT DEHYDRATASES WITH IMPROVED REACTION KINETICS E.I. du Pont de Nemours and Company (US) 2005-10-12 EP claimed
WO-2004056963-A2 B12 DEPENDENT DEHYDRATASES WITH IMPROVED REACTION KINETICS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-07-08 WO claimed
CN-1065916-C Polypeptides relating biology synthetic cobalamins and/or cobamides, coding DNA sequence of polypeptides, process for preparing them and use RHONE POULENC BIOCHIMIE (FR) 2001-05-16 CN claimed
CN-1054799-A The relevant polypeptide of biosynthesizing cobalami and/or cobamide, dna sequence dna, its preparation method and the application of these polypeptide of encoding RHONE POULENC BIOCHIMIE (FR) 1991-09-25 CN claimed
CN-86107590-A Oral administration system 1987-05-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272114-A1 Substrates for covalent tethering to proteins DDHD2, ABHD14B, AHCYL1 PIN1 334/4885LPAR3 3086/4885PLA2G4A 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.